Hostname: page-component-76fb5796d-dfsvx Total loading time: 0 Render date: 2024-04-26T01:25:33.144Z Has data issue: false hasContentIssue false
  • English
  • Français

Review of Awakening Agents

Published online by Cambridge University Press:  02 December 2014

Ryan DeMarchi ,
Vikas Bansal ,
Anthony Hung ,
Karol Wroblewski ,
Hemi Dua ,
Sanjeev Sockalingam  and
Shree Bhalerao
Ryan DeMarchi
Affiliation:
Faculty of Medicine, University of Toronto, Toronto, Ontario, Canada
Vikas Bansal
Affiliation:
Faculty of Medicine, University of Toronto, Toronto, Ontario, Canada
Anthony Hung
Affiliation:
Faculty of Medicine, University of Toronto, Toronto, Ontario, Canada
Karol Wroblewski
Affiliation:
Faculty of Medicine, University of Toronto, Toronto, Ontario, Canada
Hemi Dua
Affiliation:
Faculty of Medicine, University of Toronto, Toronto, Ontario, Canada
Sanjeev Sockalingam
Affiliation:
Faculty of Medicine, University of Toronto, Toronto, Ontario, Canada
Shree Bhalerao
Affiliation:
Medical Psychiatry Services, St. Michael’s Hospital, University of Toronto, Ontario, Canada
Rights & Permissions [Opens in a new window]

Abstract:

Core share and HTML view are not available for this content. However, as you have access to this content, a full PDF is available via the ‘Save PDF’ action button.

Brain injuries are a serious burden of illness to Canada and the US. Advances in managing head trauma have allowed more patients to emerge from decreased levels of consciousness and helped them cope with neurocognitive, neurobehavioural, and neuropsychiatric deficits. In this article, we review the current (1986-2002) evidence surrounding the pharmacological management of arousal states and the aforementioned neurological sequelae of head injury in either acute or chronic conditions. This article will review the evidence for the use of psychostimulants (methylphenidate), antidepressants (amitriptyline, selective serotonin reuptake inhibitors, and buproprion), Parkinson’s medications (amantadine, bromocriptine, carbidopa/levodopa), anticonvulsants (valproic acid), modafinil (Provigil), lactate, hyperbaric oxygen chamber, electroconvulsive therapy, and transmagnetic stimulation, in patients following a head injury. The review did not include all anticonvulsants, neuroleptics, beta-blockers, benzodiazepines, azospirones or cognitive enhancers. Unfortunately, the quality of the evidence is generally poor, and sometimes conflicting, which in turn results in indecisive guidelines for treating patients. Accepting the inherent flaws in the evidence we feel that this paper may serve as a stepping-stone for future researchers to improve data gathering that targets neurocognitive, neurobehavioural and neuropsychiatric symptoms following a head injury.

Résumé:

RÉSUMÉ:

Les traumatismes cÉrÉbraux constituent un lourd fardeau au Canada et aux États-Unis. Les progrès dans la prise en charge des traumatismes crâniens ont permis à plus de patients d’Émerger d’un niveau de conscience altÉrÉ et les ont aidÉ à s’adapter à des dÉficits neurocognitifs, neurocomportementaux et neuropsychiatriques. Dans cet article nous revoyons les donnÉes publiÉes depuis 1986 sur le traitement pharmacologique d’un État de conscience altÉrÉ et des sÉquelles neurologiques des traumatismes crâniens mentionnÉs prÉcÉdemment, en phase aiguë ou chronique. Cet article revoit les donnÉes appuyant l’utilisation de psychostimulants (mÉthylphÉnidate), d’antidÉpresseurs (amitriptyline, inhibiteurs sÉlectifs de la recaptation de la sÉrotonine et bupropion), d’anti-parkinsoniens (amantadine, bromocriptine, carbidopa/lÉvodopa), d’anticonvulsivants (acide valproïque) de modafinil (Provigil), de lactate, d’oxygÉnothÉrapie hyperbare, d’Électrochocs et de stimulation magnÉtique trans-crânienne chez des traumatisÉs crâniens. Nous n’avons pas inclus l’utilisation de tous les anticonvulsivants, de tous les neuroleptiques, bêtabloquants, benzodiazÉpines, azospirones ou facilitateurs cognitifs. Malheureusement, la qualitÉ des donnÉes est gÉnÉralement mÉdiocre et parfois elles sont contradictoires, ce qui donne lieu à des lignes directrices ambiguës quant au traitement de ces patients. Le fait de reconnaître les lacunes de ces donnÉes peut servir de prÉmices à une amÉlioration dans la collecte des donnÉes sur les symptômes neurocognitifs, neurocomportementaux et neuropsychiatriques chez les traumatisÉs crâniens.

Type
Research Article
Information
Canadian Journal of Neurological Sciences , Volume 32 , Issue 1 , February 2005 , pp. 4 - 17
Copyright
Copyright © The Canadian Journal of Neurological 2014

References

1. Thurman, D, Alverson, C, Dunn, K, Guerrero, J, Sniezek, J. Traumaticbrain injury in the United States: a public health perspective. J Head Trauma Rehabil 1999;14:602–615.CrossRefGoogle Scholar
2. Zafonte, R, Watanabe, T, Mann, N. Amantadine: a potential treatmentfor the minimally conscious state. Brain Inj 1998;12(7):617–621.CrossRefGoogle Scholar
3. Cummings, J. Neuropsychiatry and Behavioral Neurology. Washington, DC: American Psychiatric Press, Inc., 1995:212–220.Google Scholar
4. Mysiw, W, Jackson, R, Corrigan, J. Amitriptyline for post-traumaticagitation. Am J Phys Med Rehabil 1988;67(1):29–33.CrossRefGoogle Scholar
5. Wroblewski, B, Joseph, A, Kupfer, J, Kalliel, K. Effectiveness ofvalproic acid on destructive and aggressive behaviours in patients with acquired brain injury. Brain Inj 1997;11(1):37–47.CrossRefGoogle ScholarPubMed
6. O’Dell, MW, Riggs, RV. Management of the minimally responsivepatient. In: Horn, L.J, (Ed.). Medical Rehabilitation of Traumatic Brain Injury. Philadelphia: Hanley and Belfus; 1996:103–131.Google Scholar
7. Bricolo, A. Prolonged posttraumatic coma. In: Vinken, PJ, Bruyn, GW (Eds). Handbook of Clinical Neurology. Amsterdam: NorthHolland; 1976:699–755.Google Scholar
8. Multi-Society Task Force on PVS. Medical aspects of the persistentvegetative state (part 1). N Engl J Med 1994;330(21):1499–1508.CrossRefGoogle Scholar
9. Cairns, H, Oldfield, R, Pennybacker, J. Akinetic mutism with anepidermoid cyst of the 3rd ventricle. Brain 1941;64:273–290.CrossRefGoogle Scholar
10. Childs, N, Mercer, W, Ockey, R, Mowry, D, Varghese, G. Sinemet inlocked-in syndrome. Arch Phys Med Rehabil 1996; 77:523–524.CrossRefGoogle ScholarPubMed
11. Kaplan, HI, Sadock, BJ (Eds). Comprehensive Textbook ofPsychiatry/IV, Vol 1, 6th ed. Baltimore: Williams & Wilkins 1996:207–211.Google Scholar
12. Persel, CH, Persel, CS. Cornerstones of Success: Principles toMaximize Recovery from Brain Injury. Contin Care 2001; 20(4):21–23.Google Scholar
13. Van Woerkum, T, Minderhood, J, Gottschal, T. Neurotransmitters inthe treatment of patients with severe head injuries. Eur Neurol 1982;21:227–234.CrossRefGoogle Scholar
14. Wolf, A, Gleckman, A. Sinemet and brain injury: functional versusstatistical change and suggestions for future research designs. Brain Inj 1995;9(5):487–493.CrossRefGoogle ScholarPubMed
15. Naredi, S, Olivecrona, N, Lindgren, C, et al. An outcome study ofsevere traumatic head injury using the “lund therapy” with low-dose prostacyclin. Acta Anaesthesiol Scand 2001; 45:402–406.CrossRefGoogle Scholar
16. Challman, T, Lipsky, J. Methylphenidate: its pharmacology and uses. Mayo Clin Proc 2000;75:711–721.CrossRefGoogle ScholarPubMed
17. Jackson, R, Mysiw, W. Abnormal cortisol dynamics after traumaticbrain injury: lack of utility in predicting agitation or therapeutic response to tricyclic antidepressants. Am J Phys Med Rehabil 1989;68(1):18–24.CrossRefGoogle ScholarPubMed
18. Meythaler, J, Lawrence, D, Devivo, M, Guin-Renfroe, S, Novack, T. Sertraline to improve arousal and alertness in severe traumatic brain injury secondary to motor vehicle crashes. Brain Inj 2000;15(4):321–331.CrossRefGoogle Scholar
19. Teng, C, Bhalerao, S, Lee, A, et al. The use of buproprion in thetreatment of restlessness after a traumatic brain injury. Brain Inj 2001;15(5):463–467.CrossRefGoogle Scholar
20. Schneider, W, Drew-Cates, J, Wong, T, Dombovy, M. Cognitive andbehavioural efficacy of amantadine in acute traumatic brain injury: an initial double-blind placebo-controlled study. Brain Inj 1999;13(11):863–872.CrossRefGoogle Scholar
21. Zafonte, R, Lexell, J, Cullen, N. Possibleapplications for dopaminergic agents following traumatic brain injury: part 1. J Head Trauma Rehabil 2000;15(5):1179–1182.CrossRefGoogle Scholar
22. Wroblewski, B, Joseph, A, Kupfer, J, Kalliel, K. Effectiveness ofvalproic acid on destructive and aggressive behaviours in patients with acquired brain injury. Brain Inj 1997;11(1):37–47.CrossRefGoogle ScholarPubMed
23. Elovic, E. Use of provigil for underarousal following TBI. J Head Trauma Rehabil 2000;15(4):1068–1071.CrossRefGoogle ScholarPubMed
24. Rockswold, G, Ford, S, Anderson, D, Bergman, T, Sherman, R. Results of a prospective randomized trial for treatment of severely brain-injured patients with hyperbaric oxygen. J Neurosurg 1992; 76:929–934.CrossRefGoogle ScholarPubMed
25. O’Brien, D. The effective agent in electroconvulsive therapy:convulsion or coma? Med Hypotheses 1989;28:277–280.CrossRefGoogle ScholarPubMed
26. Lin, J, Hou, Y, Jouvet, M. Potential brain neuronal targets foramphetamine, methylphenidate, and modafinil-induced wakefulness, evidenced by cfos immunocytochemistry in the cat. Proc Natl Acad Sci USA 1996;93:14128–14133.CrossRefGoogle ScholarPubMed
27. Ferraro, L, Antonelli, T, Tanganelli, S. The vigilance promoting drugmodafinil increases extracellular glutamate levels in the medial preoptic area and the posterior hypothalamus of the conscious rat: Prevention by local GABAA receptor blockade. Neuropsycho-pharmacology 1999;20:346–356.CrossRefGoogle ScholarPubMed
28. Rice, A, Zsoldos, R, Chen, T, et al. Lactate administration attenuatescognitive deficits following traumatic brain injury. Brain Res 2002; 928:156–159.CrossRefGoogle ScholarPubMed
29. Marion, D. Lactate and traumatic brain injury. Crit Care Med 1999; 27(9):2063–2064.CrossRefGoogle ScholarPubMed
30. Cruz, J, Hoffstad, O, Jaggi, J. Cerebral lactate-oxygen index in acutebrain injury with acute anemia: assessment of false versus true ischemia. Crit Care Med 1994;22(9):1465–1470.CrossRefGoogle ScholarPubMed
31. Kirkcaldie, M, Pridmore, S. A bright spot on the horizon:transmagnetic stimulation in psychiatry. http://www.musc.edu/tmsmirror/intro/layintro.html.Google Scholar
32. Harbour, R, Miller, J. A new system for grading recommendations inevidence based guidelines. Br Med J 2001;323:334–336.CrossRefGoogle Scholar
33. Parikh, S. The Criteria for Level of Evidence Assignment from the Canadian Network for Mood and Anxiety Treatments (CANMAT). http://www.canmat.org.Google Scholar
34. Kraus, M. Neuropsychiatric sequelae of stroke and traumatic braininjury: the role of psychostimulants. Int J Psychiatry Med 1995;25(1):39–51.CrossRefGoogle Scholar
35. Mooney, G, Haas, L. Effect of methylphenidate on brain injury-related anger. Arch Phys Med Rehabil 1993;74:153–160.Google ScholarPubMed
36. Wroblewski, B, Leary, J, Phelan, A, Whyte, J, Manning, K. Methylphenidate and seizure frequency in brain injured patients with seizure disorders. J Clin Psychiatry 1992;53(3):86–89.Google ScholarPubMed
37. Speech, T., Rao, S, Osmon, D, Sperry, L. A double blind controlledstudy of methylphenidate treatment in closed head injury. Brain Inj 1993;7(4):333–338.CrossRefGoogle Scholar
38. Warzniak, M, Fetters, M, Comfort, M, Arber, A. Methylphenidate inthe treatment of coma. J Fam Pract 1997;44:495–498.Google Scholar
39. Kailin, C, Cifu, D, Matthies, B. Methylphenidate effect on attentiondeficit in the acutely brain-injured adult. Arch Phys Med Rehabil 1996;77:6–10.CrossRefGoogle Scholar
40. Whyte, J, Hart, T, Schuster, K, et al. Effects of methylphenidate onattentional function after traumatic brain injury. Am J Phys Med Rehabil 1997;76(6):440–450.CrossRefGoogle ScholarPubMed
41. Plenger, P, Dixon, E, Castillo, R, et al. Subacute methylphenidatetreatment for moderate to moderately severe traumatic brain injury: a preliminary double-blind placebo-controlled study. Arch Phys Med Rehabil 1996;77:536–540.CrossRefGoogle Scholar
42. Evans, R, Gualtieri, T, Patterson, D. Treatment of chronic closed headinjury with psychostimulant drugs: a controlled case study and an appropriate evaluation procedure. J Nerv Ment Dis 1987;175(2): 110.CrossRefGoogle Scholar
43. Reinhard, D, Whyte, J, Sandel, E. Improved arousal and initiationfollowing tricyclic antidepressant use in severe brain injury. Arch Phys Med Rehabil 1996;77:80–83.CrossRefGoogle ScholarPubMed
44. Fann, J, Uomaoto, , Katon, W. Cognitive improvement with treatmentof depression following mild traumatic brain injury. Psychosomatics 2001; 42(1):48–54.CrossRefGoogle Scholar
45. Stengler-Wenzke, K, Muller, U. Fluoxetine for OCD after braininjury. Am J Psychiatry 2002;159(5):872.CrossRefGoogle Scholar
46. Perino, C, Rago, R, Cicolin, A, Torta, R, Monaco, F. Mood andbehavioural disorders following traumatic brain injury: clinical evaluation and pharmacological management. Brain Inj 2001;15(2):139–148.CrossRefGoogle Scholar
47. Muller, U, Murai, T, Bauer-Wittmund, T, Cramon, D. Paroxetineversus citalopram treatment of pathological crying after braininjury. Brain Inj 1999;13(10):808–811.CrossRefGoogle Scholar
48. Meythaler, J, Brunner, R, Johnson, A, Norvack, T. Amantadine toimprove neurorecovery in traumatic brain injury - associated diffuse axonal injury: a pilot double-blind randomized trial. J Head Trauma Rehabil 2002;17(4):300–313.CrossRefGoogle Scholar
49. Nickels, J, Schneider, W, Dombovy, M, Wong, T. Clinical use ofamantadine in brain injury rehabilitation. Brain Inj 1994; 8(8):709–718.CrossRefGoogle Scholar
50. Reekum, R, Bayley, M, Garner, S, et al. N of 1 study: amantadine forthe amotivational syndrome in a patient with traumatic brain injury. Brain Inj 1995; 9(1):49–53.CrossRefGoogle Scholar
51. Kraus, M, Maki, P. The combined use of amantadine and l-dopa/caridopa in the treatment of chronic brain injury. Brain Inj 1997;11(6):455–460.CrossRefGoogle ScholarPubMed
52. Crismon, M, Childs, A, Wilcox, R, Barrow, N. The effect ofbromocriptine on speech dysfunction in patients with diffuse brain injury (akinetic mutism). Clin Neuropharmacol 1988;11(5): 462–466.CrossRefGoogle ScholarPubMed
53. Anderson, B. Relief of akineticmutism from obstructivehydrocephalus using bromocriptine and ephedrine. J Neurosurg 1992; 76:152–155.CrossRefGoogle Scholar
54. Passler, M, Riggs, R. Positive outcomes in traumatic brain injury -vegetative state: patients treated with bromocriptine. Arch Phys Med Rehabil 2001; 82:311–315.CrossRefGoogle ScholarPubMed
55. McDowell, S, Whyte, J, D’Esposito M. Differential effect of adopaminergic agonist on prefrontal function in traumatic braininjury patients. Brain 1998;121:1155–1164.CrossRefGoogle Scholar
56. Stewart, J. Akathisia following traumatic brain injury: treatment withbromocriptine. J Neurol Neurosurg Psychiatry 1989;52:1200–1201.CrossRefGoogle Scholar
57. Ockey, R, Mowry, D, Varghese, G. Use of sinemet in locked-insyndrome: a report of two cases. Arch Phys Med Rehabil 1995; 76:868–871.CrossRefGoogle ScholarPubMed
58. Haig, A, Reuss, J. Recovery from vegetative state of six months’duration associated with sinemet (levodopa/carbidopa). Arch Phys Med Rehabil 1990;71:1081–1082.Google ScholarPubMed
59. Wolf, A, Gleckman, A. Sinemet and brain injury: functional versusstatistical change and suggestions for future research designs. Brain Inj 1995;9(5):487–493.CrossRefGoogle ScholarPubMed
60. Karli, D, Burke, D, Kim, H, et al. Effects of dopaminerg i ccombination therapy for frontal lobe dysfunction in traumatic brain injury rehabilitation. Brain Inj 1999:13(1):63–68.CrossRefGoogle Scholar
61. Massagli, T. Neurobehavioural effects of phenytion, carbamazepine,and valproic acid: implications for use in traumatic brain injury. Arch Phys Med and Rehabil 1991;72:219–225.Google Scholar
62. Dikemen, S, Machamer, J, Winn, H, Anderson, G, Temkin, N. Neuropsychological effects of valproate in traumatic brain injury. Neurology 2000;54:895–902.CrossRefGoogle Scholar
63. Chatham-Showalter, P, Kimmel, DN. Agitated symptom response todivalproex following acute brain injury. J Neuropsychiatry Clin Neurosci 2000; 12(3):395–397.CrossRefGoogle ScholarPubMed
64. Kim, E, Humaran, T. Divalproexinthe management ofneuropsychiatric complications of remote acquired brain injury. J Neuropsychiatry Clin Neurosci 2002; 14(2):202–205.CrossRefGoogle ScholarPubMed
65. Saletu, B, Saletu, M, Grunberger, J, et al. Treatment of the alcoholico rganic brain syndrome: double-blind, placebo-controlled clinical, psychometric and electroencephalographic mapping studies with modafinil. Neuropsychobiology 1993;27:26–39.CrossRefGoogle Scholar
66. Teitelman, E. Off-label uses of modafinil. Am J Psychiatry 2001; 158(8):1341.CrossRefGoogle ScholarPubMed
67. Oppel, L. A review of the scientific evidence on the treatment oftraumatic brain injuries and strokes with hyperbaric oxygen. Brain Injury 2003; 17(3): 225–236.Google Scholar
68. Dean, B, Verdile, V, Krenzelok, E. Coma reversal with cerebraldysfunction recovery after repetitive hyperbaric oxygen therapy for severe carbon monoxide poisoning. Am J Emerg Med 1993;11:616–618.CrossRefGoogle ScholarPubMed
69. Baker-Price, L, Persinger, M. Weak, but complex pulsed magneticfields may reduce depression following traumatic brain injury. Percept Mot Skills 1996;83(2):491–498.CrossRefGoogle Scholar
70. Sandel, M, Mysiw, W. The agitated brain-injured patient. Part 1:definition, differential diagnosis and assessment. Arch Phys Med Rehabil 1996;77:617–623.CrossRefGoogle Scholar
71. Wang, R. Glasgow coma scale, brain electric activity mapping andGlasgow coma scale after hyperbaric oxygen treatment of severe brain injury. Chin J Traumatol 2001;4(4):239–241.Google Scholar
72. Ruedrich, S, Chu, C, Moore, S. ECT for major depression in a patientwith acute brain trauma. Am J Psychiatry 1983 Jul; 140(7): 928–929.Google Scholar
73. Wijeratne, C, Shome, S. Electroconvulsive therapy and subduralhemorrhage. J ECT 1999;15(4):275–279.CrossRefGoogle Scholar
74. Crow, S, Meller, W, Christenson, G, Mackenzie, T. Use of ECT afterbrain injury. Convuls Ther 1996;12(2):113–116.Google Scholar
75. Kant, R, Bogyi, A, Carosella, N, et al. ECT as a therapeutic option insevere brain injury. Convuls Ther 1995;11(1):45–50.Google Scholar
76. Kant, R, Coffey, C, Bogyi, A. Safety and efficacy of ECT in patientswith head injury: a case series. J Neuropsychiatry Clin Neurosci 1999;11(1):32–37.CrossRefGoogle Scholar